Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Repligen Corporation (NasdaqNM:RGEN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Options | Financials
Location
117 Fourth Avenue
Needham, MA 02494
Phone: (781) 449-9560
Fax: (781) 453-0048
Email: investors@repligen.com
Employees (last reported count): 40
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 37%
·Over the last 6 months:
 · 2 insider buys; 30.0K shares (0.3% of insider shares)
 · 3 insider sells; 876.0K shares
  (8.2% of insider shares)
·Institutional: 30% (48% of float)
(27 institutions)
·Net Inst. Buying: 619.0K shares (+7.15%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Repligen Corporation develops new drugs for autism, immune system diseases and mitochondrial disease. The Company's lead therapeutic products are secretin for autism, CTLA4-Ig for stem cell transplantation and uridine for mitochondrial disease. The Company also manufactures and markets products based on Protein A for the purification of antibodies, and it owns commercial rights to two products based on synthetic forms of secretin for the diagnosis of pancreatic function.
More from Market Guide: Expanded Business Description

Financial Summary
Repligen develops new drugs based on naturally occurring peptides and proteins for autism, organ transplantation and immune system diseases. For the three months ended 6/30/01, revenues increased 8% to $713 thousand. Net loss increased 38% to $1.3 million. Revenues reflect a large-scale production order of Protein A. Higher loss suffered from increased costs associated with drug development programs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2001 Pay

Alexander Rich, M.D., 76
Co-Chairman
--  
Paul Schimmel, Ph.D., 60
Co-Chairman
--  
Walter Herlihy, Ph.D., 49
Pres, CEO, Treasurer, Director
$260K
James Rusche, Ph.D., 47
VP- R&D
175K
Daniel Witt, Ph.D., 53
VP-Bus. Devel., Sec.
152K
Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:RGENAs of 31-Aug-2001
Price and Volume
52-Week Low
on 17-Apr-2001
$1.28 
Recent Price$2.25 
52-Week High
on 3-Nov-2000
$8.688
Beta-0.02 
Daily Volume (3-month avg)95.6K
Daily Volume (10-day avg)208.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-71.9%
52-Week Change
relative to S&P500
-62.3%
Share-Related Items
Market Capitalization$59.9M
Shares Outstanding26.6M
Float16.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.11 
Earnings (ttm)-$0.21 
Earnings (mrq)-$0.05 
Sales (ttm)$0.09 
Cash (mrq)$0.96 
Valuation Ratios
Price/Book (mrq)2.03 
Price/EarningsN/A 
Price/Sales (ttm)24.97 
Income Statements
Sales (ttm)$2.40M
EBITDA (ttm)-$7.26M
Income available to common (ttm)-$5.65M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsMar 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-17.61%
Return on Equity (ttm)-18.28%
Financial Strength
Current Ratio (mrq)24.62 
Debt/Equity (mrq)0 
Total Cash (mrq)$25.5M
Short Interest
As of 8-Aug-2001
Shares Short165.0K
Percent of Float1.0%
Shares Short
(Prior Month)
167.0K
Short Ratio2.32 
Daily Volume71.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.